US Pharma MarketingA 10-year push for more biosimilars in the U.S. has led to a surge in copycat entrants, bringing more attention to the legal barriers.
As biosimilars gain US traction, patent thickets are under more scrutiny
<figure><div><img src="https://imgproxy.divecdn.com/J8TLqokr0nkDomTwtfX1jmQiuPKKjDuK8Iblt1qSQko/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xOTEyMDg4MDQ2LmpwZw==.webp"/></div></figure><p>A 10-year push for more biosimilars in the U.S. has led to a surge in copycat entrants, bringing more attention to the legal barriers.</p>
Source: PharmaVoice